1. Generics Bulletin
  2. >>Products

Generics Bulletin Explains: The Next Wave Of US Humira Biosimilars

Start Of July Will See An Explosion Of Competition On Adalimumab In US From Eight Rivals

 
• By Dave Wallace

Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.

Black running track with white markings for positions 1 to 8
Eight further FDA-approved Humira biosimilars are set to launch • Source: Shutterstock

Anyone with even a passing interest in the global off-patent industry will likely be aware of the significance of 2023 for the US biosimilars market.

FDA-approved adalimumab biosimilars

Amgen’s Amjevita (adalimumab-atto)

Biocon’s Hulio (adalimumab-fkjp)

Boehringer Ingelheim’s Cyltezo (adalimumab-adbm)

Celltrion’s Yuflyma (adalimumab-aaty)

Coherus’s Yusimry (adalimumab-aqvh)

Fresenius Kabi’s Idacio (adalimumab-aacf)

Pfizer’s Abrilada (adalimumab-afzb)

Samsung Bioepis/Organon’s Hadlima (adalimumab-bwwd)

Sandoz’s Hyrimoz (adalimumab-adaz)

Humira – for a long time the world’s top-selling drug, and still one of the biggest brands in the business...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By Dave Wallace

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

Amgen Stands Firm On IV Checkpoint Inhibitor Biosimilars

 
• By Dean Rudge

Amgen continues to advance its intravenous biosimilar programs for key immuno-oncology agents, including its ABP 234 biosimilar to Keytruda and ABP 206 biosimilar to Opdivo, despite growing interest in subcutaneous formulations enabled by hyaluronidase technology.

‘Concrete Solutions, Not Big Words’ – Samsung Bioepis Suggests European Improvements For Biosimilars

 
• By Dave Wallace

While biosimilars have seen success in Europe, there are still plenty of areas in which policy improvements could solve problems for the market, according to a new Samsung Bioepis white paper. Adam Levysohn, the firm’s local head of commercial strategy, talks about the proposals.